Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lili Sheng

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Gut Microbes|June 10, 2020
Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specificallyJunli Ma, Ying Hong, Ningning Zheng, et al.
Renal Failure|July 24, 2023
Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective studyXiaoyan Ma, Lu Fang, Lili Sheng, et al.
Pharmacological Research|August 19, 2024
Gut microbiota-brain bile acid axis orchestrates aging-related neuroinflammation and behavior impairment in miceJunli Ma, Mingxiao Li, Yiyang Bao, et al.
Nature Communications|September 6, 2023
Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttlingJing Zhong, Xiaofang He, Xinxin Gao, et al.
Cell Reports. Medicine|March 20, 2024
Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturationWeize Zhu, Ying Hong, Zhaowei Tong, et al.
Cancer Management and Research|August 22, 2020
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from ChinaWanren Peng, Fenglin Zhang, Zishu Wang, et al.
Journal of Bone Oncology|February 25, 2025
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumorsMingchuan Zhao, Xichun Hu, Pengpeng Zhuang, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Gut Microbes|June 10, 2020
Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specificallyJunli Ma, Ying Hong, Ningning Zheng, et al.
Renal Failure|July 24, 2023
Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective studyXiaoyan Ma, Lu Fang, Lili Sheng, et al.
Pharmacological Research|August 19, 2024
Gut microbiota-brain bile acid axis orchestrates aging-related neuroinflammation and behavior impairment in miceJunli Ma, Mingxiao Li, Yiyang Bao, et al.
Nature Communications|September 6, 2023
Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttlingJing Zhong, Xiaofang He, Xinxin Gao, et al.
Cell Reports. Medicine|March 20, 2024
Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturationWeize Zhu, Ying Hong, Zhaowei Tong, et al.
Cancer Management and Research|August 22, 2020
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from ChinaWanren Peng, Fenglin Zhang, Zishu Wang, et al.
Journal of Bone Oncology|February 25, 2025
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumorsMingchuan Zhao, Xichun Hu, Pengpeng Zhuang, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 11